Cognition Therapeutics (NASDAQ:CGTX) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Cognition Therapeutics (NASDAQ:CGTX) in a report published on Monday,Benzinga reports. HC Wainwright currently has a $5.00 price target on the stock.

A number of other analysts have also weighed in on CGTX. Chardan Capital restated a “buy” rating and set a $11.00 target price on shares of Cognition Therapeutics in a research note on Thursday, October 31st. Cantor Fitzgerald lowered shares of Cognition Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, July 30th. Finally, B. Riley reaffirmed a “neutral” rating and set a $1.00 price objective (down from $5.00) on shares of Cognition Therapeutics in a research report on Tuesday, August 6th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Cognition Therapeutics Trading Up 4.1 %

Cognition Therapeutics stock opened at $0.52 on Monday. The firm has a market capitalization of $20.88 million, a P/E ratio of -0.55 and a beta of 1.34. Cognition Therapeutics has a twelve month low of $0.34 and a twelve month high of $2.95. The stock’s fifty day simple moving average is $0.52 and its 200-day simple moving average is $1.27.

Cognition Therapeutics (NASDAQ:CGTX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.04. During the same period in the previous year, the company posted ($0.16) EPS. Sell-side analysts predict that Cognition Therapeutics will post -0.96 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Bangor Savings Bank lifted its position in Cognition Therapeutics by 41.6% in the second quarter. Bangor Savings Bank now owns 34,019 shares of the company’s stock valued at $56,000 after acquiring an additional 10,000 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its holdings in shares of Cognition Therapeutics by 33.4% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock valued at $159,000 after purchasing an additional 24,050 shares during the last quarter. CM Management LLC boosted its position in shares of Cognition Therapeutics by 14.3% in the 2nd quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $332,000 after purchasing an additional 25,000 shares during the period. Sigma Planning Corp grew its stake in Cognition Therapeutics by 14.6% during the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after buying an additional 25,050 shares during the last quarter. Finally, Tocqueville Asset Management L.P. acquired a new position in Cognition Therapeutics during the first quarter worth approximately $47,000. Institutional investors and hedge funds own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.